Luxna Biotech Overview

  • Founded
  • 2017

Founded
  • Status
  • Private

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $10.7M

  • Investors
  • 7

Luxna Biotech General Information

Description

Developer of nucleic acid drugs intended to contribute to medical treatment for suffering patients. The company's drugs are based on a licensed cross-linked modified nucleic acid group that offers the advantage of being safer because it binds strongly to the target mRNA, obtains better efficacy, and reduces the risk of hepatotoxicity, enabling hospitals to provide alternatives to patients who fight diseases without effective drugs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • C907 9F Building C
  • Techno-Alliance Complex, 2-8 Yamadaoka
  • Suita-shi, Osaka 565-0871
  • Japan
+81 00-0000-0000

Luxna Biotech Timeline

2019202020212022
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Luxna Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 16-Dec-2021 $10.7M 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series A) 10-Feb-2020 00.000 00.000 000.00 Completed Generating Revenue
1. Early Stage VC 01-Mar-2018 $927K $927K 00.000 Completed Generating Revenue
To view Luxna Biotech’s complete valuation and funding history, request access »

Luxna Biotech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
C preferred 0,000 00000.00 00000.00 00 00000.00 00.000
B preferred 0,000 00000 00000 00 00000 00.000
A preferred 500 $1757.2 $1757.2 1x $1757.2 10.81%
To view Luxna Biotech’s complete cap table history, request access »

Luxna Biotech Executive Team (1)

Name Title Board Seat Contact Info
Hideaki Sato Chief Executive Officer & President
To view Luxna Biotech’s complete executive team members history, request access »

Luxna Biotech Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Japan Finance Corporation Lender/Debt Provider Minority 000 0000 000000 0
Ikeda Senshu Capital Venture Capital Minority 000 0000 000000 0
Mizuho Venture Capital Venture Capital Minority 000 0000 000000 0
Nissan Chemical Corporation Minority 000 0000 000000 0
Shinsei Capital Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »